Achilles doses first patient

Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma. This is the first tumour-infiltrating lymphocyte (TIL) therapy to enter clinical trials where the TILs have been specifically selected to target clonal neoantigens – antigens which are believed to be present on all tumour cells.

Back to News and insights